PDF(Pubmed)
Abstract：
Doxorubicin (DOX) is a broad-spectrum and highly efficient anticancer agent, but its clinical implication is limited by lethal cardiotoxicity. Growing evidences have shown that alterations in intestinal microbial composition and function, namely dysbiosis, are closely linked to the progression of DOX-induced cardiotoxicity (DIC) through regulating the gut-microbiota-heart (GMH) axis. The role of gut microbiota and its metabolites in DIC, however, is largely unelucidated. Our review will focus on the potential mechanism between gut microbiota dysbiosis and DIC, so as to provide novel insights into the pathophysiology of DIC. Furthermore, we summarize the underlying interventions of microbial-targeted therapeutics in DIC, encompassing dietary interventions, fecal microbiota transplantation (FMT), probiotics, antibiotics, and natural phytochemicals. Given the emergence of microbial investigation in DIC, finally we aim to point out a novel direction for future research and clinical intervention of DIC, which may be helpful for the DIC patients.
摘要：
多柔比星(DOX)是一种广谱高效的抗癌剂,但其临床意义受到致死性心脏毒性的限制。越来越多的证据表明，肠道微生物组成和功能的改变，即生态失调，通过调节肠道-微生物群-心脏（GMH）轴与DOX诱导的心脏毒性（DIC）的进展密切相关。肠道菌群及其代谢产物在DIC中的作用，然而,在很大程度上是无法阐明的。我们的综述将集中在肠道菌群失调和DIC之间的潜在机制。从而为DIC的病理生理学提供新的见解。此外，我们总结了DIC中微生物靶向治疗的潜在干预措施，包括饮食干预，粪便微生物移植（FMT），益生菌，抗生素,和天然植物化学物质。鉴于DIC中微生物研究的出现，最后，我们旨在为DIC的未来研究和临床干预指出一个新的方向，这可能对DIC患者有帮助。
